Bradley Hunter, MD
Medical Oncology · Salt Lake City, UTNPI 1235556382
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Gilead at 54.2% of the total. Among medical oncology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $1202.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$143K
- AbbVie$29K
- Novartis$28K
- E.r. Squibb & Sons, L.L.C.$16K
- Genmab U.S., Inc.$13K
- Regeneron$10K
- plus $25K from 13 others
Across 150 payments — averaging $20,223 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hoffmann-la Roche Limited$1.2M
- Roche Products Limited$494K
- Janssen Scientific Affairs, LLC$397K
- AbbVie$239K
- Genentech, Inc.$190K
- Bristol Myers Squibb$165K
- plus $376K from 7 others
What the payments were for
- Consulting fees$100,01738%
- Speaking & faculty fees$133,54551%
- Travel & lodging$24,5809%
- Food & beverage$5,1322%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 101 | $142,643 |
| AbbVie | 29 | $28,767 |
| Novartis | 24 | $27,926 |
| E.r. Squibb & Sons, L.L.C. | 12 | $15,888 |
| Genmab U.S., Inc. | 8 | $13,156 |
| Regeneron | 10 | $10,028 |
| Genentech, Inc. | 5 | $5,312 |
| Johnson & Johnson | 6 | $4,791 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $3,023 |
| Janssen Scientific Affairs, LLC | 4 | $2,676 |
| Astellas Pharma Global Development | 1 | $2,500 |
| Bristol Myers Squibb | 7 | $2,486 |
| ADC Therapeutics America, Inc. | 1 | $2,000 |
| Janssen Global Services, LLC | 1 | $1,500 |
| Incyte Corporation | 2 | $237 |
| Telix Pharmaceuticals | 1 | $188 |
| Daiichi Sankyo Inc. | 1 | $151 |
| AstraZeneca | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$263,300 in reported general payments places this provider in the 95th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Salt Lake City
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Ignacio Garrido-LagunaSalt Lake City$35K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Paul ShamiSalt Lake City$28K
- Nitin ChandramouliSalt Lake City$19K
- Kenneth GrossmannSalt Lake City$15K
- Manish KohliSalt Lake City$13K
- Peter HaleSalt Lake City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.